Challenging Assumptions About Immunosuppression in Fibrotic ILD

Q: What does this research mean for the field?

Current assumptions regarding the efficacy and role of immunosuppression in fibrotic interstitial lung disease are flawed and require significant re-evaluation. Novelty: ClaimNovelty.CONTRADICTORY. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

Scott M. Matson; Yet H Khor

doi:10.1093/ajrccm/aamag411

September 11, 2026American Journal of Respiratory and Critical Care MedicineOpen Access

Challenging Assumptions About Immunosuppression in Fibrotic ILD

View Full Paper

Ask AI

Bookmark

Share

Key Points

To re-examine prevailing paradigms and clinical evidence surrounding the therapeutic efficacy and safety of immunosuppressive therapy across fibrotic interstitial lung diseases.
Critical narrative review evaluating clinical trial data, historical perspectives, and phenotypic classifications of fibrotic interstitial lung disease treated with immunosuppressive regimens.
Challenges widespread assumptions that immunosuppressive regimens are uniformly harmful or ineffective across all fibrotic pulmonary phenotypes.
Emphasizes the clinical need to distinguish inflammatory from purely fibrotic disease drivers to optimize the timing and selection of immunosuppressive versus antifibrotic agents.

Implication

Clinical review examines treatment paradigms in fibrotic interstitial lung disease, suggesting current immunosuppression practices warrant re-evaluation.

Abstract

Scott M Matson, Yet H Khor; Challenging Assumptions About Immunosuppression in Fibrotic ILD, American Journal of Respiratory and Critical Care Medicine, ,

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Matson et al. (2026) studied this question.

synapsesocial.com/papers/6aa7b3580926e14a848b21d6 https://doi.org/10.1093/ajrccm/aamag411

View Full Paper

Ask AI

Bookmark

Share

Challenging Assumptions About Immunosuppression in Fibrotic ILD

Key Points

Implication

Abstract

Discussion

Cite This Study

Challenging Assumptions About Immunosuppression in Fibrotic ILD

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading